- Trial Phase
- Phase 2
- Time to Market
- Unknown — development is likely paused or halted due to the company's cash crisis. Any path to market would require an asset sale to a better-capitalized partner.
- Why 3/10
- No hard dated catalyst (PDUFA, pivotal readout, or regulatory decision) is scheduled for ozuriftamab vedotin within the next ~12 months. The drug is a development-stage asset at a company with only ~$1.5M cash that has paused operations. The next potential catalyst is an asset-sale announcement from the ongoing strategic alternatives process, but this has no fixed date and is a corporate transaction, not a binary clinical/regulatory catalyst. Per the rubric, an asset with no upcoming regulatory binary scores a maximum of 5 even if central to the company — here the score is capped at 3 because the drug's development is effectively on hold and the stock is a distressed OTC microcap.
The stock (BCAB, OTC) is a distressed microcap with existential going-concern risk. Ozuriftamab vedotin's value will be determined by the ongoing strategic alternatives process — watch for asset-sale announcements or a licensing deal as the most plausible near-term catalyst. The Yorkville $40M SEPA facility threatens severe dilution if the company draws on it. This is not a binary-drug-investment scenario; it is a distressed-asset-sale thesis.
Price Chart
Executive Summary
Ozuriftamab vedotin (development code BA3011) is BioAtla's conditionally active biologic (CAB) antibody-drug conjugate targeting AXL, a receptor tyrosine kinase overexpressed in multiple solid tumors, conjugated to a vedotin (MMAE) payload. The drug is a clinical-stage asset, but the headline story is the developer's severe financial distress: BioAtla has only ~$1.5M cash (as of June 2026), was delisted from Nasdaq in August 2026, enacted a 70% workforce reduction in early 2026, and is pursuing a formal strategic alternatives process (asset sales, licensing, or a sale of the company). The company has substantial doubt about its ability to continue as a going concern, and any near-term value for ozuriftamab vedotin would likely come through an asset sale or partnership, not a fundamental clinical/regulatory catalyst.
How It Works
Ozuriftamab vedotin is a precision cancer drug — an antibody-drug conjugate (ADC) that works like a guided missile. The antibody part targets a protein called AXL found on the surface of many solid tumor cells. It carries a chemotherapy payload (MMAE, a microtubule-disrupting toxin) attached via a linker. BioAtla's 'Conditionally Active Biologic' (CAB) technology is designed to make the antibody only bind to AXL in the acidic, low-oxygen environment of a tumor, potentially reducing damage to healthy tissue. Once bound, the tumor cell internalizes the ADC and releases the chemotherapy payload to kill it.
Trial Status
Ozuriftamab vedotin was evaluated in Phase 1/2 clinical trials for multiple solid tumor types, but BioAtla's severe financial distress — 70% workforce reduction, Nasdaq delisting, and only $1.5M cash as of June 2026 — has likely halted or severely curtailed ongoing development. The company is pursuing a formal strategic alternatives process to monetize all assets, including this drug candidate.
The Two-Sided Case
Upcoming Catalysts
- Strategic alternatives process outcome (asset sale, licensing deal, or company sale) — no public deadline
- Possible Yorkville SEPA draw filings (dilution risk)
- No hard clinical/regulatory catalyst dated in the next 12 months
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BioAtla, Inc. S-1 BCAB ·Originating report